tbuckley/cabot-search huggingface dataset:
SAT0290 A Higher Disease Activity in Anti-Ssa/ssb Positive Sjögren's Syndrome Is Explained by A Higher Clinical and Biological B-Cell Activation: Table 1
Authors: L. Quartuccio, C. Baldini, E. Bartoloni, F. Carubbi, A. Alunno, R. Priori, R. Gerli, G. Valesini, R. Giacomelli, S. Bombardieri, S. De Vita
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Anti-SSA/SSB positive Sjögren9s syndrome is characterized by a higher risk for developing lymphoma (1), but no data already exist on systemic disease activity in subgroups of SS, as measured by validated scores for primary SS, such as the ESSDAI or ClinESSDAI. <h3>Objectives</h3> Primary objective of the study was to demonstrate the differences between anti-SSA/SSB positive and anti-SSA/SSB negative SS patients as regards systemic disease activity. <h3>Methods</h3> 955 patients affected by primary SS were included. All patients fulfilled the American-European Consensus Group Criteria for primary SS. Patients showing isolated anti-SSB positivity were excluded from these analyses. Patients were 911 female (95,4%), with a mean age of 52±14 years. ESSDAI and ClinESSDAI scores were measured (2, 3). Mann-Whitney U test was used to compare the ESSDAI and ClinESSDAI scores between anti-SSA/SSB positive and negative patients. <h3>Results</h3> Patients with anti-SSA with or without anti-SSB antibodies were 684 (71.6%), while anti-SSA and anti-SSB antibody negative patients were 271 (28.4%). Median (range) ESSDAI and median (range) ClinESSDAI were 5 (0–54) and 6 (0–53) in anti-SSA/SSB positive patients, and 4 (0–63) and 4 (0–60) in anti-SSA/SSB negative patients, respectively. Both the ESSDAI and the ClinESSDAI scores were significantly higher in anti-SSA/SSB positive patients (p&lt;0.001 and p=0.021, respectively). Importantly, these differences were determined by a significant difference in the frequency of some domains, i.e., "lymphadenopathy" (p=0.034, Chi-square test), "glandular" (p=0.0004, Chi-square test), "cutaneous" (p=0.017, Chi-square test), "hematological" (p&lt;0.0001, Chi-square test) and "biological" (p&lt;0.0001, Chi-square test) (table 1). Notably, anti-SSA/SSB positive patients were younger than anti-SSA/SSB negative patients (50±14 vs. 57±11 years, p&lt;0.0001 by t-test). Rheumatoid factor positivity (p&lt;0.0001, Chi-square test), low C3 (p&lt;0.0001, Chi-square test), low C4 (p=0.045, Chi-square test) and the presence of serum cryoglobulins (p=0.022, Chi-square test) were also significantly linked to the presence of anti-SSA/SSB positivity. <h3>Conclusions</h3> Clinical and biological signs of B-cell lymphoproliferation more specifically characterized anti-SSA/SSB positive patients, glandular, hematological and biological domains showing the most significant differences. This feature appears to clearly differentiate Sjögren9s disease from Sjögren9s syndrome. <h3>References</h3> Quartuccio L, et al. Autoimmun Rev. 2015;14:1019–22. Seror R, et al. Ann Rheum Dis 2010;69:1103–9. Seror R, et al. Ann Rheum Dis 2015;74:579 <h3>Disclosure of Interest</h3> None declared
Do we really need the full compliance with ERAS protocol in laparoscopic colorectal surgery? A prospective cohort study
Authors: Magdalena Pisarska, Michał Pędziwiatr, Piotr Małczak, Piotr Major, Sebastian Ochenduszko, Anna Zub-Pokrowiecka, Jan Kulawik, Andrzej Budzyński
Journal: International Journal of Surgery (2016)
AB0687 Cardiovascular Morbidity and Mortality of Patients with Spondyloarthritis, Results of 10-Year Prospective Controlled Study
Authors: I. Gaydukova, A. Rebrov, A. Akulova, A. Aparkina, E. Khondkaryan
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Cardiovascular events are the leading cause of mortality in arthritis. However, data of cardiovascular (CV) morbidity and mortality in spondyloarthritis (SpA) are contradictory. Current data about CV mortality and morbidity in SpA in Russian population are limited. <h3>Objectives</h3> The aim of the study was to evaluate CV morbidity and mortality in patients with SpA. <h3>Methods</h3> 676 patients with SpA without CV diseases were involved, 160 healthy individuals included as controls. In 10 years of follow-up CV events (cardiac death, angina, myocardial infarction (MI), stroke, arterial hypertension (AH), arrhythmias or conduction disturbances) were recorded. Statistical analysis was performed using SPSS17. <h3>Results</h3> 313 patients and 10 controls had loss the follow-up. From 363 patients with 10-year results 278 had axial SpA (axSpA), 85 – psoriatic arthritis (PsA)). Mean age±SD was 40.1±14.1 years in SpA, 40.0±11.4 in axSpA, 40.55±10.6 in PsA, 39.0±11.2 in controls, p≥0.05 for all. Prevalence of male was recorded in axSpA compared with PsA (p=0.02), other groups were matched in gender, p≥0.05 (69.7% males in SpA, 76.3% in axSpA, 48.2% in PsA, and 56% in controls). Smoking was frequently occurred in axSpA (68%, p&lt;0.05 with all the other groups). Frequency of CV events is presented in table. Arrhythmias were recorded in 55 (15.2%), conduction disorders – in 48 (13.22%), stroke – in 9 (2.47%) SpA patients. Odds ratio (OR) of death in SpA as compared to controls was 4.6 (95% confidential interval (CI) 0.4–10.6), p&gt;0.05, in PsA OR=8.0 (CI 5.7–16.1) compared to controls and 9.9 (CI 6.0–18.1), compared to axSpA, p&lt;0.0001 for all, image. Relative risk (RR) of MI in axSpA was 1.77 (CI 1.5–2.1), in PsA – 4.3 (CI 2.5–14.5), compared to controls, p&lt;0.0001 for all. In controls risk of MI was comparable with expected population level (RR 1.24, CI 0.96–1.59). In axSpA RR for AH = 2.23 (CI 1.6–3.1), in PsA RR = 3.09 (CI 2.19–4.35), p&lt;0.0001 compared to controls. <h3>Conclusions</h3> CV mortality in SpA and axSpA is comparable to population level, in PsA is higher, than in healthy controls and in ax-SpA. The incidence of angina, MI, AH in patients with ax-SpA and PsA exceeds the incidence in healthy controls. <h3>Disclosure of Interest</h3> None declared
Improvement of idiopathic membranous nephropathy diagnosis with ultrasensitive quantitative detection of anti-phospholipase A2 receptor
Authors: Biao Huang, Liang Wang, Ya-nan Cao, Yi Zhang, Jue Zhang, Hualong Xiao, Qiuhua Zhang, Weidong Wang, Zhuxing Sun, Yu Chen, Zhigang Hu, Huiming Sheng
Journal: Journal of Allergy and Clinical Immunology (2016)
Escalated Dose Bortezomib Once Weekly Combined with Lenalidomide and Dexamethasone (eVRD) Followed by Lenalidomide Maintenance in First Relapse of Multiple Myeloma (MM). the HOVON 86 Phase 2 Trial
Authors: Pieter Sonneveld, Okke de Weerdt, Mark-David Levin, Wendimagegn Ghidey, Edo Vellenga, Saskia K Klein, Jeanette Doorduyn, Marie José Kersten, P.W. Wijermans, Henk Lokhorst
Journal: Blood (2012)
Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL): A Comparison between French -Belgian-Swiss and Spanish Results.
Authors: L. Ades, M. Sanz, S. Chevret, S. De Botton, G. Martin, E. Raffoux, E. Vellenga, A. Guerci, M. Gonzalez, A. Pigneux, C. Rayon, A.M. Stoppa, J. De la Serna, T. Pabst, S. Meyer-Monard, R. Parodi, J. Bergua, F. Rigal-Huguet, A. Vekhoff, S. Negri, N. Fegueux, A. Ferrant, D. Bron, H. Dombret, L. Degos, P. Fenaux
Journal: Blood (2005)
SAT0035 Regulatory CD4+ T-Cell Levels and Anti Citrullinated Protein Antibody Repertoire as Biomarkers for Arthritis Development in Seropositive Arthralgia Patients
Authors: K. Janssen, J. Westra, P. Chalan, A. Boots, M. de Smit, A.J. van Winkelhoff, A. Vissink, E. Brouwer
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Early diagnosis and treatment of rheumatoid arthritis (RA) is of paramount importance for achieving a better disease outcome. Seropositive arthralgia patients (SAP), positive for anti citrullinated protein antibody (ACPA) and/or rheumatoid factor (RF) with (a history of) arthralgia, have a “high risk” of developing RA. Therefore it is necessary to understand which preclinical immunological factors play a role in the progression towards RA in SAP since this could help identify individuals earlier and result in early intervention. <h3>Objectives</h3> This prospective study aimed at identifying whether altered regulatory T-cells (Tregs) levels and subsets, besides a broadened ACPA response, are biomarkers for RA development in SAP. <h3>Methods</h3> Thirty-four consecutive SAP were prospectively assessed every 6 months for at least 2 years. Every visit, peripheral blood mononuclear cells (PBMCs) were isolated and stored. At inclusion, peripheral Treg (CD4<sup>+</sup>CD25<sup>+</sup>FoxP3<sup>+</sup>) levels and Treg subsets, defined as CD45RA<sup>+</sup>FoxP3<sup>low</sup> naive Treg cells (Fr I), CD45RA<sup>–</sup>FoxP3<sup>high</sup> activated Treg cells (Fr II) and cytokine producing CD45RA<sup>–</sup>FoxP3<sup>low</sup> non-Treg cells (Fr III), were compared to age and sex matched healthy controls (HC, n=16) and treatment naive RA patients (n=12). SAP that developed RA during follow-up were compared to non-switchers on Treg levels and functional Treg subsets. To assess broadening of the IgG and IgA ACPA repertoire in serum, reactivity was measured against citrullinated peptides from fibrinogen, α-enolase and vimentin. <h3>Results</h3> Total Treg levels were similar between HC, SAP and RA patients. Although functional Treg subsets Fr I and Fr II were comparable between groups, Fr III was increased in SAP compared to HC (p=0.01). Fourteen (41%) SAP developed RA during follow-up. Their Treg levels were comparable to those of non-switched SAP. At RA diagnosis, Treg levels in switched SAP were not changed compared to 6 months before. Switched SAP displayed an extended IgG ACPA repertoire compared to non-switched SAP (p=0.046). <h3>Conclusions</h3> Total and functional Treg levels do not indicate development of RA in SAP, in contrast to an extended IgG and IgA ACPA repertoire. Hence, there is presumably no contribution of altered Treg levels leading to the loss in suppression of autoimmunity in RA pathology. <h3>Disclosure of Interest</h3> None declared
Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Is Superior to 6 Courses CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT In Mantle Cell Lymphoma: Results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net)
Authors: Olivier Hermine, Eva Hoster, Jan Walewski, Vincent Ribrag, Nicole Brousse, Catherine Thieblemont, Reda Bouabdallah, Stephan Stilgenbauer, Pierre Feugier, Roswitha Forstpointner, Corinne Haioun, Michael Kneba, Mathias Hänel, Rene-Olivier Casasnovas, Jürgen Finke, Michael Hallek, Hannes Wandt, Andre Bosly, Wolfram Klapper, Christian Gisselbrecht, Bertrand Coiffier, Wolfgang Hiddemann, Michael Unterhalt, Martin H. Dreyling
Journal: Blood (2010)
AB0473 Quality of Life in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis Measured by The SF36
Authors: M.I. Acosta Colman, L. Roman, S. Cabrera, G. Avila Pedretti, M.E. Acosta Colman, E. Rojas, Y. Yinde, J. Losanto, M. Duarte
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Systemic Lupus Erythematosus (SLE) and rheumatoid arthritis (RA) are autoimmune diseases that mainly affect people in the reproductive stage of their life; it is interesting to investigate the impact of both diseases have in patient9s quality of life. <h3>Objectives</h3> The main objective of this study was to evaluate the quality of life of patients diagnosed with SLE and RA using the SF36 questionnaire and the factors that influence it <h3>Methods</h3> Analytical, observational cross-sectional study of a cohort of SLE and RA patients. A large number of clinical and epidemiological variables were recorded (i.e. years of evolution, the age at diagnosis, disease activity, gender, marital status, etc). Quality of life was determined by SF36 questionnaire. Statistical analysis was performed with SPSS19.0 program. Qualitative variables were expressed as percentages and frequencies while quantitative were informed as mean and standard deviation. Association was analyzed with X2 test and Student T test. Pearson9s test was used for correlation analysis. <h3>Results</h3> 112 patients were studied, 50.9% (57/112) patients had SLE and 49.1% (55/112) RA. 69.6% (78/112) of patients came from the capital city and metropolitan area. 87.5% (90/112) were female, 57.14% (64/112) were living in couple and 49.1% (55/100) had basic education. 43.8% (49/97) perceive less or equal to the minimum wage monthly income. 42% (47/98) were living with 3 or fewer inhabitants in the house and 58.9% (66/108) had ≥40 years old at disease onset. The mean value of physical (PCS) component of SF36 questionnaire in SLE and RA was 45.13±12.5 and 47.7±12.5 respectively and the difference between them was significantly (p=0.01). On the other hand, the mean value of mental (MCS) component was 47.7±12.5 and 46.4±12 respectively but no significant difference was found (p=0.58). In relation to the 8 SF36 components we found significant difference between them, principally in the components that measures body pain (p=0.0001) and health perception (p=0.047). In SLE patients, a significant negative correlation it was found between PCS and HAQ (p=0.00018) and SLEDAI (p=0.0020). No significantly correlation with MCS was found. Regarding the SLICC Score, a statistically negative correlation was found with MCS (p=0.036). In RA patients, a significant negative correlation was found between PCS and HAQ (p=0.0001), no association with the DAS28 was found. But, a negative correlation between the MCS and DAS28 (p=0.03) was found. No significant correlation was observed with HAQ. <h3>Conclusions</h3> In this cohort revealed that physical and mental component of SF36 are influenced by the disease activity and functional impairment. <h3>Acknowledgement</h3> Sr Horacio Medina <h3>Disclosure of Interest</h3> None declared
WT1 Protein Expression in Myeloid Malignancies: An Immunohistochemical Study
Authors: Anna Mozos, Elena Bussaglia, Maite Carricondo, Camino Estivill, Pablo Fuentes, Tatjana Dedjulia, Matilde Parreno, Anna Aventin, Jorge Sierra, Jaime Prat, Josep Nomdedeu
Journal: Blood (2011)
AB0007 Genome-Wide Association Study of Clinical Phenotypes in Psoriatic Arthritis
Authors: J. Cañete, J.A. Pinto, J. Gratacos, R. Queiro, C. Montilla, J.C. Torre-Alonso, J.J. Perez-Venegas, A. Fernández Nebro, S. Muñoz, C. Gonzalez, D. Roig, P. Zarco, A. Erra, J. Rodriguez, S. Castañeda, E. Rubio, G. Salvador, C. Diaz, R. Blanco, A. Willisch, J.A. Mosquera, P. Vela, J. Tornero, S. Sanchez, H. Corominas, J. Ramirez, M. Lopez-Lasanta, M. Lόpez-Corbeto, R. Tortosa, A. Julià, S. Marsal
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Genome-wide association studies (GWAS) in Psoriatic Arthritis (PsA)patients and controls have allowed the identification of multiple variants associated with disease risk. To date, however, no GWAS for PsA phenotypes has been reported. <h3>Objectives</h3> The main objective of this study was to identify new genetic variation associated with clinical phenotypes in PsA. <h3>Methods</h3> A total of n=835 patients diagnosed with PsA using CASPAR criteria were recruited in the discovery stage and genotyped for &gt;600,000 single nucleotide polymorphisms. GWAS were performed for clinical and biological phenotypes associated with joint and skin disease. After allelic association analysis, those SNPs with highest level of significance were analyzed in an independent cohort of n=414 PsA patients. <h3>Results</h3> In the GWAS stage, several genomic regions showing high evidence of association with different PsA phenotypes (P&lt;5e-6) were identified, including axial disease, peripheral disease, bone proliferation, degree of radiological sacroileitis and the presence of syndesmophytes. Also, GWAS on cutaneous phenotypes identified two regions associated with nail disease and skin disease severity. Using the replication cohort, the association between one locus and peripheral pattern, and two loci with axial pattern were validated. <h3>Conclusions</h3> Usign a GWAS approach, new loci associated with axial and peripheral disease in PsA have been identified. <h3>Disclosure of Interest</h3> None declared
THU0205 Association between Concurrent Methotrexate and Trimethoprim-Sulfamethoxazole Use and The Risk of Hospitalisation in Patients with Rheumatoid Arthritis: A Nationwide Population Study
Authors: T.-T. Chuang, C.-H. Yang, C.-F. Kuo, S.-F. Luo, K.-H. Yu, L.-C. See
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Concurrent use of methotrexate (MTX) and trimethoprim-sulfamethoxazole (TMP-SMX) has been linked to the development of cytopenia as a result of reduced renal clearance of MTX. However, the risk of adverse outcomes has not been estimated in a population setting. <h3>Objectives</h3> This study aimed to examine the risk for emergency department visits or hospitalisation after concurrent use of MEX and TMP-SMX in patients with rheumatoid arthritis (RA) in Taiwan using the National Health Insurance (NHI) data. <h3>Methods</h3> This was a retrospective cohort analysis of RA patients identified from the entire NHI database which contains essentially all residents in Taiwan. The case definition of RA was based on a rheumatologist diagnosis with a verification of expert panel commissioned by the Administration of National Health Insurance. Overall we identified 30,285 RA patients between 2000 and 2010. RA patients filled prescription for MTX in 453,114 person-quarters in which 9018 person-quarters they also filled a prescription for TMP-SMX. The main outcome measure was emergency department visit or hospital admission in person-quarters with concurrent fills of MTX and TMP-SMX compared with the rates in person-quarters with MTX prescription only. Multivariable logistic regression was used to adjust for age, sex, comorbidity, and socioeconomic status with a Generalised Estimating Equation (GEE) model to calculated the crude ORs (95% CIs) and adjusted ORs. <h3>Results</h3> Hospitalisations were more common in person-quarters with MTX and TMP-SMX use (688 events/8330 quarters) compared with quarters with MTX use alone (20,616 events/423,480 quarters) with a crude OR of 1.49 (95% confidence interval [CI], 1.36–1.62] and an adjusted OR of 1.45 (95% CI, 1.33–1.58). However, the risk for emergency department visits associated with MTX and TMP-SMX use (536 events/8,482 person-quarters) was not higher (21,115 events/422,981 person-quarters). The crude OR was 1.08 (95% CI, 0.97–1.19) for emergency department visits and the adjusted OR was 1.05 (95% CI 0.95–1.15]). <h3>Conclusions</h3> MTX use along with TMP-SMX is associated with an increased risk for hospitalisations which suggests a significant drug interaction between MTX and TMP-SMX in RA patients. <h3>Disclosure of Interest</h3> None declared
Fewer Relapses Following Unrelated Donor Cord Blood (UDCB) Compared to Related or Unrelated Bone Marrow (BM) or Peripheral Blood Cell (PBSC) Transplant in the Treatment of Childhood Relapsed and Very High Risk Acute Lymphoblastic Leukemia (ALL).
Authors: Donna A. Wall, Ka Wah Chan, Bess Bowen, Lorraine Alexander, Michael Grimley
Journal: Blood (2006)
Phase I Trial of Bortezomib (NSC 681239) and Flavopiridol (NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms.
Authors: Steven Grant, Daniel Sullivan, David Roodman, Robert K Stuart, Edward Perkins, Sarah Kolla, Viswanathan Ramakrishnan, John Wright, Alexander Dimitri Colevas, M B Tombes, John D Roberts
Journal: Blood (2008)
Distinct Pattern of Genomic Changes Associated with Hypoplastic Compared to Hyper/Normoblastic Myelodysplastic Syndromes (MDS)
Authors: Aziz Nazha, David J. Seastone, Tomas Radivoyevitch, Brittney Dienes, Bartlomiej Przychodzen, Sean Hobson, Sudipto Mukherjee, Hetty E. Carraway, Jennifer S Carew, Anjali S. Advani, Aaron T. Gerds, Hideki Makishima, Mikkael A. Sekeres, Jaroslaw P. Maciejewski
Journal: Blood (2014)
Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas
Authors: Ganesh M. Shankar, Malak Abedalthagafi, Rachael A. Vaubel, Parker H. Merrill, Naema Nayyar, Corey M. Gill, Ryan Brewster, Wenya Linda Bi, Pankaj K. Agarwalla, Aaron R. Thorner, David A. Reardon, Ossama Al-Mefty, Patrick Y. Wen, Brian M. Alexander, Paul van Hummelen, Tracy T. Batchelor, Keith L. Ligon, Azra H. Ligon, Matthew Meyerson, Ian F. Dunn, Rameen Beroukhim, David N. Louis, Arie Perry, Scott L. Carter, Caterina Giannini, William T. Curry, Daniel P. Cahill, Frederick G. Barker, Priscilla K. Brastianos, Sandro Santagata
Journal: Neuro-Oncology (2016)

Patients with meningiomas have widely divergent clinical courses. Some entirely recover following surgery alone, while others have relentless tumor recurrences. This clinical conundrum is exemplified by rhabdoid meningiomas, which are designated in the World Health Organization Classification of Tumours as high grade, despite only a subset following an aggressive clinical course. Patient management decisions are further exacerbated by high rates of interobserver variability, biased against missing possibly aggressive tumors. Objective molecular determinants are needed to guide classification and clinical decision making.To define genomic aberrations of rhabdoid meningiomas, we performed sequencing of cancer-related genes in 27 meningiomas from 18 patients with rhabdoid features and evaluated breast cancer [BRCA]1-associated protein 1 (BAP1) expression by immunohistochemistry in 336 meningiomas. We assessed outcomes, germline status, and family history in patients with BAP1-negative rhabdoid meningiomas.The tumor suppressor gene BAP1, a ubiquitin carboxy-terminal hydrolase, is inactivated in a subset of high-grade rhabdoid meningiomas. Patients with BAP1-negative rhabdoid meningiomas had reduced time to recurrence compared with patients with BAP1-retained rhabdoid meningiomas (Kaplan-Meier analysis, 26 mo vs 116 mo, P < .001; hazard ratio 12.89). A subset of patients with BAP1-deficient rhabdoid meningiomas harbored germline BAP1 mutations, indicating that rhabdoid meningiomas can be a harbinger of the BAP1 cancer predisposition syndrome.We define a subset of aggressive rhabdoid meningiomas that can be recognized using routine laboratory tests. We implicate ubiquitin deregulation in the pathogenesis of these high-grade malignancies. In addition, we show that familial and sporadic BAP1-mutated rhabdoid meningiomas are clinically aggressive, requiring intensive clinical management.
Incidence, Risk Factors for Early Hepatotoxicity and Its Impact on Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplantation
Authors: Kit Man Wong, Eshetu G Atenafu, Dennis Dong Hwan Kim, John Kuruvilla, Jeffrey H. Lipton, Hans A. Messner, Vikas Gupta
Journal: Blood (2011)